Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $2

Outlook Therapeutics, Inc. -0.92% Pre

Outlook Therapeutics, Inc.

OTLK

8.62

8.62

-0.92%

0.00% Pre

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ: OTLK) with a Buy and raises the price target from $1.5 to $2.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via